Ala F Nassar, PhD
Research & Publications
Biography
News
Research Summary
Our areas of expertise include drug metabolism, bioanalytical chemistry and mass spectrometry. Mass spectrometry makes it possible to identify hundreds or even thousands of different proteins in a mixture of molecules. We used several mass spec tools to study the ADME-Tox properties of new molecules. Also, we applied single-cell resolution capabilities of proteomics and metabolomics to seek deeper understanding of biology and cellular heterogeneity. Such studies should help facilitate new target and biomarker discovery in drug development and translational research.
Extensive Research Description
Our research focuses on understanding how structure modification can improve the ADME-Tox profile for new chemical entities as they advance toward clinical candidacy. Our recent efforts use Mass Cytometry & MALDI-IHC as novel tools for Cancer Research. With their capacity for tremendous detail, these techniques produce enhanced investigative power for analyses involving simultaneous cellular profiling of multiple cell populations. Our latest endeavors are focused on an advance in single cell analysis using a hybrid mass spectrometry-flow cytometry instrument to identify and characterize rare cell types in clinical samples. Another emphasis is the development of mass spectrometric and proteomic methods for application in biological and clinical contexts to identify and quantify proteins with greater depth and coverage in a single cell.
Coauthors
Research Interests
Metabolism; Pharmacology; Mass Spectrometry; Proteomics; Metabolomics; Single-Cell Analysis
Public Health Interests
Cancer
Research Image
Workflow of mass cytometry analysis
A liquid sample containing cells labeled with heavy metal isotope-conjugated probes (ICPs) (a) is introduced into the nebulizer (b), where it is aerosolized. The aerosol droplets are directed into the ICP torch (c),
where the cells are vaporized, atomized, and ionized. Low-mass ions are
removed in the radiofrequency (RF) quadrupole ion guide (d), resulting in a cloud of ions enriched for the probe isotopes. The ion cloud then enters the time-of-flight (TOF) chamber (e),
where the ions are separated on the basis of their mass:charge ratio as
they accelerate toward the detector. Thus, the time-resolved detector
measures a mass spectrum (f) that represents the identity and quantity of each isotope on a per cell basis. Data are generated in .fcs format (g) and analyzed using the cloud-based Cytobank platform (h).
Selected Publications
- Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New DrugsNASSAR A. Drug Design Strategies: Role of Structural Modifications of Drug Candidates to Improve PK Parameters of New Drugs 2022, 323-343. DOI: 10.1002/9781119851042.ch10.
- Accelerating Metabolite Identification Mass Spectrometry Technology Drives Metabolite Identification Studies ForwardNASSAR A. Accelerating Metabolite Identification Mass Spectrometry Technology Drives Metabolite Identification Studies Forward 2022, 267-302. DOI: 10.1002/9781119851042.ch8.
- Case Study: Metabolism and Reactions of Alkylating Agents in Cancer TherapyNASSAR A, WISNEWSKI A, KING I. Case Study: Metabolism and Reactions of Alkylating Agents in Cancer Therapy 2022, 893-922. DOI: 10.1002/9781119851042.ch26.
- Role of Structural Modifications of Drug Candidates to Enhance Metabolic StabilityNassar A. Role of Structural Modifications of Drug Candidates to Enhance Metabolic Stability 2022, 303-322. DOI: 10.1002/9781119851042.ch9.
- Chemical Structural Alert and Reactive Metabolite Concept as Applied in Medicinal Chemistry to Minimize the Toxicity of Drug CandidatesNASSAR A. Chemical Structural Alert and Reactive Metabolite Concept as Applied in Medicinal Chemistry to Minimize the Toxicity of Drug Candidates 2022, 345-372. DOI: 10.1002/9781119851042.ch11.
- Drug Metabolism Handbook: Concepts and Applications in Cancer ResearchJohn Wiley & Sons.
- Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.
- A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer ImmunotherapySanmamed MF, Nie X, Desai SS, Villaroel-Espindola F, Badri T, Zhao D, Kim AW, Ji L, Zhang T, Quinlan E, Cheng X, Han X, Vesely MD, Nassar AF, Sun J, Zhang Y, Kim TK, Wang J, Melero I, Herbst RS, Schalper KA, Chen L. A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy Cancer Discovery 2021, 11: 1700-1715. PMID: 33658301, PMCID: PMC9421941, DOI: 10.1158/2159-8290.cd-20-0962.
- PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosusHan X, Vesely MD, Yang W, Sanmamed MF, Badri T, Alawa J, López-Giráldez F, Gaule P, Lee SW, Zhang JP, Nie X, Nassar A, Boto A, Flies DB, Zheng L, Kim TK, Moeckel GW, McNiff JM, Chen L. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus Science Translational Medicine 2019, 11 PMID: 31826980, DOI: 10.1126/scitranslmed.aax1159.
- LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate.Wisnewski AV, Liu J, Nassar AF. LC-UV-MS and MS/MS Characterize Glutathione Reactivity with Different Isomers (2,2' and 2,4' vs. 4,4') of Methylene Diphenyl-Diisocyanate. EC Pharmacology And Toxicology 2019, 7: 205-219. PMID: 31143884, PMCID: PMC6536005.
- Dilysine-Methylene Diphenyl Diisocyanate (MDI), a Urine Biomarker of MDI Exposure?Wisnewski AV, Nassar AF, Liu J, Bello D. Dilysine-Methylene Diphenyl Diisocyanate (MDI), a Urine Biomarker of MDI Exposure? Chemical Research In Toxicology 2019, 32: 557-565. PMID: 30724074, PMCID: PMC6465083, DOI: 10.1021/acs.chemrestox.8b00262.
- Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human PlasmaNassar AF, Wisnewski AV, Wu T, Lam TT, King I. Development and Validation of LC–MS-MS Assay for the Determination of the Emerging Alkylating Agent Laromustine and Its Active Metabolite in Human Plasma Journal Of Chromatographic Science 2018, 57: 195-203. PMID: 30395213, DOI: 10.1093/chromsci/bmy100.
- Polymerization of hexamethylene diisocyanate in solution and a 260.23 m/z [M+H]+ ion in exposed human cellsWisnewski AV, Liu J, Redlich CA, Nassar AF. Polymerization of hexamethylene diisocyanate in solution and a 260.23 m/z [M+H]+ ion in exposed human cells Analytical Biochemistry 2017, 543: 21-29. PMID: 29175138, PMCID: PMC5826792, DOI: 10.1016/j.ab.2017.11.017.
- Reaction products of hexamethylene diisocyanate vapors with “self” molecules in the airways of rabbits exposed via tracheostomyWisnewski AV, Kanyo J, Asher J, Goodrich JA, Barnett G, Patrylak L, Liu J, Redlich CA, Nassar AF. Reaction products of hexamethylene diisocyanate vapors with “self” molecules in the airways of rabbits exposed via tracheostomy Xenobiotica 2017, 48: 488-497. PMID: 28489470, PMCID: PMC5863241, DOI: 10.1080/00498254.2017.1329569.
- Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimizationNassar AF, Wisnewski AV, Raddassi K. Automation of sample preparation for mass cytometry barcoding in support of clinical research: protocol optimization Analytical And Bioanalytical Chemistry 2017, 409: 2363-2372. PMID: 28124752, PMCID: PMC5863240, DOI: 10.1007/s00216-017-0182-4.
- UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical researchNassar AF, Wu T, Nassar SF, Wisnewski AV. UPLC–MS for metabolomics: a giant step forward in support of pharmaceutical research Drug Discovery Today 2016, 22: 463-470. PMID: 27919805, PMCID: PMC5721520, DOI: 10.1016/j.drudis.2016.11.020.
- Corrigendum to “Identification of novel reaction products of methylene-biS-phenylisocyanate (“MDI”) with oxidized glutathione in aqueous solution and also during incubation of MDI with a murine hepatic S9 fraction” [Toxicol. In vitro (2016) 97–104]Wisnewski AV, Liu J, Nassar AF. Corrigendum to “Identification of novel reaction products of methylene-biS-phenylisocyanate (“MDI”) with oxidized glutathione in aqueous solution and also during incubation of MDI with a murine hepatic S9 fraction” [Toxicol. In vitro (2016) 97–104] Toxicology In Vitro 2016, 38: 193. PMID: 27784537, DOI: 10.1016/j.tiv.2016.10.008.
- Identification of novel reaction products of methylene-bis-phenylisocyanate (“MDI”) with oxidized glutathione in aqueous solution and also during incubation of MDI with a murine hepatic S9 fractionWisnewski AV, Liu J, Nassar AF. Identification of novel reaction products of methylene-bis-phenylisocyanate (“MDI”) with oxidized glutathione in aqueous solution and also during incubation of MDI with a murine hepatic S9 fraction Toxicology In Vitro 2016, 36: 97-104. PMID: 27453132, PMCID: PMC5010927, DOI: 10.1016/j.tiv.2016.07.011.
- Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patientsNassar AF, Wisnewski AV, King I. Population pharmacokinetic (PK) analysis of laromustine, an emerging alkylating agent, in cancer patients Xenobiotica 2016, 47: 394-407. PMID: 27440490, DOI: 10.1080/00498254.2016.1201703.
- Progress in automation of mass cytometry barcoding for drug developmentNassar AF, Wisnewski AV, Raddassi K. Progress in automation of mass cytometry barcoding for drug development Bioanalysis 2016, 8: 1429-1435. PMID: 27323800, DOI: 10.4155/bio-2016-0135.
- Biotransformation and Rearrangement of LaromustineNassar AE, Wisnewski AV, King I. Biotransformation and Rearrangement of Laromustine Drug Metabolism And Disposition 2016, 44: 1349-1363. PMID: 27278961, DOI: 10.1124/dmd.116.069823.
- Mass cytometry moving forward in support of clinical research: advantages and considerationsNassar AF, Wisnewski AV, Raddassi K. Mass cytometry moving forward in support of clinical research: advantages and considerations Bioanalysis 2016, 8: 255-257. PMID: 26847541, DOI: 10.4155/bio.15.257.
- Rapid label‐free profiling of oral cancer biomarker proteins using nano‐UPLC‐Q‐TOF ion mobility mass spectrometryNassar AF, Williams BJ, Yaworksy DC, Patel V, Rusling JF. Rapid label‐free profiling of oral cancer biomarker proteins using nano‐UPLC‐Q‐TOF ion mobility mass spectrometry Proteomics Clinical Applications 2016, 10: 280-289. PMID: 26684082, DOI: 10.1002/prca.201500025.
- In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1Wisnewski AV, Liu J, Nassar AF. In vitro cleavage of diisocyanate-glutathione conjugates by human gamma-glutamyl transpeptidase-1 Xenobiotica 2015, 46: 726-732. PMID: 26678254, PMCID: PMC4848134, DOI: 10.3109/00498254.2015.1118576.
- Impact of recent innovations in the use of mass cytometry in support of drug developmentNassar AF, Ogura H, Wisnewski AV. Impact of recent innovations in the use of mass cytometry in support of drug development Drug Discovery Today 2015, 20: 1169-1175. PMID: 26092491, PMCID: PMC4668584, DOI: 10.1016/j.drudis.2015.06.001.
- Metabolic disposition of the anti-cancer agent [14C]laromustine in male ratsNassar AF, Wisnewski A, King I. Metabolic disposition of the anti-cancer agent [14C]laromustine in male rats Xenobiotica 2015, 45: 711-721. PMID: 25798740, PMCID: PMC4681490, DOI: 10.3109/00498254.2015.1016475.
- Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M).Nassar AE, King I, Du J. Characterization of short-lived electrophilic metabolites of the anticancer agent laromustine (VNP40101M). Chem Res Toxicol 2011, 24: 568-78. PMID: 21361357, DOI: 10.1021/tx100453t.
- Case Study: The Unanticipated Loss of N2 from Novel DNA Alkylating Agent Laromustine by Collision‐Induced Dissociation: Novel RearrangementsNassar A, Du J, Roberts D, Lin K, Belcourt M, King I, Lam T. Case Study: The Unanticipated Loss of N2 from Novel DNA Alkylating Agent Laromustine by Collision‐Induced Dissociation: Novel Rearrangements 2010, 217-228. DOI: 10.1002/9780470890387.ch5.
- Case Study: Identification of in vitro Metabolite/Decomposition Products of the Novel DNA Alkylating Agent LaromustineNassar A, Du J, Roberts D, Lin K, Belcourt M, King I, Lam T. Case Study: Identification of in vitro Metabolite/Decomposition Products of the Novel DNA Alkylating Agent Laromustine 2010, 229-244. DOI: 10.1002/9780470890387.ch6.
- Tools of Choice for Accelerating Metabolite Identification: Mass Spectrometry Technology Drives Metabolite Identification Studies ForwardNassar A. Tools of Choice for Accelerating Metabolite Identification: Mass Spectrometry Technology Drives Metabolite Identification Studies Forward 2010, 125-162. DOI: 10.1002/9780470890387.ch3.
- Improving Drug Design: Considerations for the Structural Modification ProcessNassar A. Improving Drug Design: Considerations for the Structural Modification Process 2010, 163-216. DOI: 10.1002/9780470890387.ch4.
- Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and DevelopmentNassar A. Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development 2010, 1-23. DOI: 10.1002/9780470571224.pse108.
- Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design StrategiesNassar A. Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design Strategies 2010, 1-13. DOI: 10.1002/9780470571224.pse110.
- Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic StabilityNassar A. Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability 2010, 1-16. DOI: 10.1002/9780470571224.pse109.
- Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical DevelopmentNassar A. Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development 2010, 1-24. DOI: 10.1002/9780470571224.pse111.
- Biotransformation and metabolite elucidation of xenobiotics 1st ed. John Wiley & Sons
- An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes.Nassar AE, King I, Paris BL, Haupt L, Ndikum-Moffor F, Campbell R, Usuki E, Skibbe J, Brobst D, Ogilvie BW, Parkinson A. An in vitro evaluation of the victim and perpetrator potential of the anticancer agent laromustine (VNP40101M), based on reaction phenotyping and inhibition and induction of cytochrome P450 enzymes. Drug Metab Dispos 2009, 37: 1922-30. PMID: 19520774, DOI: 10.1124/dmd.109.027516.
- Drug Metabolism Handbook: Concepts and Applications 1st edJohn Wiley & Sons
- Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical DevelopmentNassar A. Minimizing the Potential for Drug Bioactivation of Drug Candidates to Success in Clinical Development 2008, 283-306. DOI: 10.1002/9780470439265.ch12.
- Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design StrategiesNassar A. Structural Modifications of Drug Candidates: How Useful Are They in Improving PK Parameters of New Drugs? Part II: Drug Design Strategies 2008, 269-281. DOI: 10.1002/9780470439265.ch11.
- Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and DevelopmentNassar A. Approaches to Performing Metabolite Elucidation: One Key to Success in Drug Discovery and Development 2008, 229-251. DOI: 10.1002/9780470439265.ch9.
- Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic StabilityNassar A. Structural Modifications of Drug Candidates: How Useful Are They in Improving Metabolic Stability of New Drugs? Part I: Enhancing Metabolic Stability 2008, 253-268. DOI: 10.1002/9780470439265.ch10.
- Novel approach to performing metabolite identification in drug metabolism.Nassar AE, Lee DY. Novel approach to performing metabolite identification in drug metabolism. J Chromatogr Sci 2007, 45: 113-9. PMID: 17462124, DOI: 10.1093/chromsci/45.3.113.
- Drug interactions: concerns and current approaches.Nassar AE, Talaat RE, Tokuno H. Drug interactions: concerns and current approaches. IDrugs 2007, 10: 47-52. PMID: 17187315.
- The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet?Nassar AE, Talaat RE, Kamel AM. The impact of recent innovations in the use of liquid chromatography-mass spectrometry in support of drug metabolism studies: are we all the way there yet? Curr Opin Drug Discov Devel 2006, 9: 61-74. PMID: 16445118.
- Improving the decision-making process in structural modification of drug candidates: reducing toxicity.Nassar AE, Kamel AM, Clarimont C. Improving the decision-making process in structural modification of drug candidates: reducing toxicity. Drug Discov Today 2004, 9: 1055-64. PMID: 15582794, DOI: 10.1016/S1359-6446(04)03297-0.
- Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability.Nassar AE, Kamel AM, Clarimont C. Improving the decision-making process in the structural modification of drug candidates: enhancing metabolic stability. Drug Discov Today 2004, 9: 1020-8. PMID: 15574318, DOI: 10.1016/S1359-6446(04)03280-5.
- Liquid chromatography-accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies.Nassar AE, Parmentier Y, Martinet M, Lee DY. Liquid chromatography-accurate radioisotope counting and microplate scintillation counter technologies in drug metabolism studies. J Chromatogr Sci 2004, 42: 348-53. PMID: 15355573, DOI: 10.1093/chromsci/42.7.348.
- Strategies for dealing with metabolite elucidation in drug discovery and development.Nassar AE, Talaat RE. Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today 2004, 9: 317-27. PMID: 15037231, DOI: 10.1016/S1359-6446(03)03018-6.
- Detecting and Minimizing Reactive Intermediates in R&DCurrent Drug Discovery
- Strategies for dealing with reactive intermediates in drug discovery and development.Nassar AE, Lopez-Anaya A. Strategies for dealing with reactive intermediates in drug discovery and development. Curr Opin Drug Discov Devel 2004, 7: 126-36. PMID: 14982156.
- Metabolite Characterization- One Key to Success in Drug DiscoveryPharmaTech. 2004; :46-51.
- Online hydrogen-deuterium exchange and a tandem-quadrupole time-of-flight mass spectrometer coupled with liquid chromatography for metabolite identification in drug metabolism.Nassar AE. Online hydrogen-deuterium exchange and a tandem-quadrupole time-of-flight mass spectrometer coupled with liquid chromatography for metabolite identification in drug metabolism. J Chromatogr Sci 2003, 41: 398-404. PMID: 14558931, DOI: 10.1093/chromsci/41.8.398.
- Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction.Nassar AE, Adams PE. Metabolite characterization in drug discovery utilizing robotic liquid-handling, quadruple time-of-flight mass spectrometry and in-silico prediction. Curr Drug Metab 2003, 4: 259-71. PMID: 12871044, DOI: 10.2174/1389200033489406.
- On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development.Nassar AE, Bjorge SM, Lee DY. On-line liquid chromatography-accurate radioisotope counting coupled with a radioactivity detector and mass spectrometer for metabolite identification in drug discovery and development. Anal Chem 2003, 75: 785-90. PMID: 12622367, DOI: 10.1021/ac025934f.
- Quantitative analysis of hydrocortisone in human urine using a high-performance liquid chromatographic-tandem mass spectrometric-atmospheric-pressure chemical ionization method.Nassar AE, Varshney N, Getek T, Cheng L. Quantitative analysis of hydrocortisone in human urine using a high-performance liquid chromatographic-tandem mass spectrometric-atmospheric-pressure chemical ionization method. J Chromatogr Sci 2001, 39: 59-64. PMID: 11245227, DOI: 10.1093/chromsci/39.2.59.
- Determination of chemical warfare agent degradation products at low-part-per-billion levels in aqueous samples and sub-part-per-million levels in soils using capillary electrophoresis.Nassar AE, Lucas SV, Hoffland LD. Determination of chemical warfare agent degradation products at low-part-per-billion levels in aqueous samples and sub-part-per-million levels in soils using capillary electrophoresis. Anal Chem 1999, 71: 1285-92. PMID: 10204034, DOI: 10.1021/ac980886d.
- Atmospheric Pressure Chemical Ionization/Mass Spectrometry and Capillary Electrophoresis for the Analysis of Chemical Warfare Agent Degradation ProductsIn: Scamehorn JF, editor. In Surfactant-Based Separations: Recent Advances USA: ACS Symposium Series, Vol. 740; 1999. Chapter 20; p.329–350.
- Quantitative analysis of chemical warfare agent degradation products in reaction masses using capillary electrophoresis.Nassar AE, Lucas SV, Myler CA, Jones WR, Campisano M, Hoffland LD. Quantitative analysis of chemical warfare agent degradation products in reaction masses using capillary electrophoresis. Anal Chem 1998, 70: 3598-604. PMID: 9737210, DOI: 10.1021/ac9713870.
- Separation of chemical warfare agent degradation products by the reversal of electroosmotic flow in capillary electrophoresis.Nassar AE, Lucas SV, Jones WR, Hoffland LD. Separation of chemical warfare agent degradation products by the reversal of electroosmotic flow in capillary electrophoresis. Anal Chem 1998, 70: 1085-91. PMID: 9530000, DOI: 10.1021/ac9709716.
- Optimizing a Method for Separations of Chiral Compounds by Capillary Electrophoresis. J. Chromarogr. ScienceJournal of Chromatographic Science
- Salt and pH effects on electrochemistry of myoglobin in thick films of a bilayer-forming surfactant.Nassar AE, Rusling JF, Kumosinski TF. Salt and pH effects on electrochemistry of myoglobin in thick films of a bilayer-forming surfactant. Biophys Chem 1997, 67: 107-16. PMID: 9397521, DOI: 10.1016/s0301-4622(97)00027-6.
- Direct Electron Injection from Electrodes to Cytochrome P450cam in Biomembrane-Iike Films. J. Chem. Soc., Faraday Trans
- Electrochemistry of Cast Films of Ferredoxin and Lipid Bilayers on Electrodes. J. Electroanal. Chem
- Electron transfer from electrodes to myoglobin: facilitated in surfactant films and blocked by adsorbed biomacromolecules.Nassar AE, Willis WS, Rusling JF. Electron transfer from electrodes to myoglobin: facilitated in surfactant films and blocked by adsorbed biomacromolecules. Anal Chem 1995, 67: 2386-92. PMID: 8686876, DOI: 10.1021/ac00110a010.
- Electrochemical Properties of Myog1obin Embedded in Langmuir-Blodgett and Cast Films of Synthetic Lipids. J. Chem. Soc., Faraday Trans
- Orientation of Myoglobin in Cast Multibilayer Membranes of Amphiphilic Molecules. J. Physical Chemistry
- Films formed by oxidation of ferrocene at platinum electrodes.Kamau GN, Saccucci TM, Gounili G, Nassar AE, Rusling JF. Films formed by oxidation of ferrocene at platinum electrodes. Anal Chem 1994, 66: 994-1001. PMID: 8160965, DOI: 10.1021/ac00079a011.
- Indirect Spectrometric Determination of Phosphate by Atomic Absorption. Int. J. BioChemPhys.
- Effect of Coagulants and Extent of Color Removal from Textile Effluents. Int. J. BioChemPhys
- Spectroscopy and Molecular Modeling of Electrochemically Active Films of Myoglobin and Didodecyldimetbyl Ammonium Bromide. In: Kumosinski TF, Liebman MN, editors. In Molecular Modeling, ACS Symposium Series 576 USA: ACS